<DOC>
	<DOCNO>NCT01654484</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy three concentration DE-117 ophthalmic solution ( Low Dose , Medium Dose , High Dose ) monotherapy adjunctive therapy ( DE-117 ophthalmic solution 0.0015 % tafluprost ) subject primary open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>A Study Assessing Safety Efficacy DE-117 Ophthalmic Solution Patients With POAG OHT</brief_title>
	<detailed_description>This two stage study . Stage One explore dose response three concentration DE-117 monotherapy compare 0.0015 % tafluprost placebo . The safety efficacy DE-117 adjunctive therapy ( 0.0015 % tafluprost ) compare 0.0015 % tafluprost placebo also evaluate . In addition , additive effect adjunctive therapy concentration compare corresponding monotherapy concentration . Stage Two assess safety efficacy optimal DE-117 concentration monotherapy compare 0.0015 % tafluprost . The safety efficacy optimal DE-117 concentration adjunctive therapy ( 0.0015 % tafluprost ) compare DE-117 monotherapy 0.0015 % tafluprost also evaluate .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Male Female , 18 year age old 2 . Current diagnosis primary openangle glaucoma ocular hypertension eye 3 . Qualifying intraocular pressure ( IOP ) least one eye Baseline 1 . Closed/barely open anterior chamber angle history acute angle closure either eye 2 . Anticipate need initiate modify medication ( systemic topical ) know affect intraocular pressure ( IOP ) study period 3 . Females pregnant , nurse plan pregnancy 4 . Presence abnormality significant illness could expect interfere study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>